KYTHERA Biopharmaceuticals, Inc. KYTH today presented positive
results that found MRI measurements of patients treated with ATX-101
demonstrated a statistically significant reduction in submental fat
(SMF), commonly known as double chin, during an oral session at The
Aesthetic Meeting 2013, organized by the American Society for Aesthetic
Plastic Surgery (ASAPS), April 11-16, New York, NY. MRI assessments were
performed in the study as a quantifiable and objective measure of
submental fat volume and thickness. The same study also demonstrated
positive results based on validated clinician- and patient-reported
outcome measures. The results are from a Phase IIb, multicenter,
randomized, double-blind, placebo-controlled study (ATX-101-09-15) to
evaluate the safety and efficacy of ATX-101, a potential first-in-class,
non-surgical, injectable
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in